News for Healthier Living

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leading biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced positive topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy(r) in overweight and obese adults.

November 18, 2025


November 18 2025

November 17 2025

November 16 2025

November 15 2025

November 14 2025

November 13 2025

November 12 2025

November 11 2025

November 10 2025

November 9 2025

November 8 2025

November 7 2025

November 6 2025

November 5 2025

November 4 2025